- US12247038utility2025Pyrido[3,2-d]pyrimidine Compounds as Immunomodulators0 cites
- US12233067utility2025Topical Treatment of Vitiligo by a JAK Inhibitor0 cites
- US12226418utility2025Dosing Regimen for the Treatment of PI3K Related Disorders0 cites
- US12214036utility2025Combination Therapy Comprising AXL/MER and PD-1/PD-L1 Inhibitors0 cites
- US12203942utility2025Biomarkers for Graft-versus-host Disease0 cites
- US12194095utility2025Combinations and Uses Thereof0 cites
- US12187725utility2025Tricyclic Urea Compounds as JAK2 V617F Inhibitors0 cites
- US12187730utility2025Salts of TAM Inhibitors0 cites
- US12187743utility2025Heterocyclic Compounds as Immunomodulators0 cites
- US12173006utility2024Crystalline Forms of a Phosphoinositide 3-kinase (PI3K) Inhibitor0 cites
- US12168660utility2024Derivatives of an FGFR Inhibitor0 cites
- US12150943utility2024JAK1 Pathway Inhibitors for the Treatment of Gastrointestinal Disease0 cites
- US12129267utility2024Heteroaryl Amide Compounds as Sting Activators0 cites
- US12122767utility2024Bicyclic Heterocycles as FGFR Inhibitors0 cites
- US12099068utility2024Biomarkers for Graft-versus-host Disease0 cites
- US12083124utility2024Bicyclic Heterocycles as FGFR Inhibitors0 cites
- US12084430utility2024Tricyclic Urea Compounds as JAK2 V617F Inhibitors0 cites
- US12084443utility2024Process of Preparing a PD-1/PD-L1 Inhibitor0 cites
- US12084449utility2024Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors0 cites
- US12084453utility2024Bicyclic Amines as CDK12 Inhibitors0 cites